Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs
This article was originally published in The Pink Sheet Daily
Executive Summary
Two venture firms bet on the Scottish university spin-out, now based California, as it develops pro-drugs activated by a specific enzyme family.
You may also be interested in...
Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
Making The Case For Antibody-Drug Conjugates
After 30 years and one market failure, antibody-drug conjugate developers have produced two strong clinical candidates, with a lot more coming in the pipeline. Can two successes turn into the next great therapeutic platform?
Ablexis' Pharmaceutical Consortium
Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.